Blogs
Why did we say yes to SuperBeings?
Abhishek has always passionately backed companies which question the paradigm and solve a problem. Superbeings, was no exception.He says " Even though there are several companies addressing the broken pieces of the problem, today’s fast-paced and high growth environment needs an intuitive cohesive platform for the new normal focusing on Individual Transformation and Organisational Growth in whole."
Why did we invest in Synapsica?
Dr Ramesh Byrapaneni breaks down his investment rationale for Synapsica.“My belief is that technology, would not do away with specialized manpower, what it aims to do is further strengthen and empower the abilities and decision-making for the specialists.” He says.Read on to know what fuels a strong decision to partner and invest.
The Eyestem Story: Why did we invest in?
Dr Ramesh Byrapaneni says" I believe that the time for cell therapy solutions has arrived and the starting point to this promising area of science has to be the eye, the retina, to be specific. Eyestem intends to disrupt the global cell therapy ecosystem and set a new benchmark for quality and affordability in this sector. Eyecyte-RPE, their flagship solutions to treat incurable age related macular degeneration has excellent efficacy results and will be in 'First in Man' (FIM) trials in 2021."
2022 All rights reserved
